Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored.
Two Value Stocks to Sell:
Reynolds (REYN)
Forward P/E Ratio: 13.7x
Best known for its aluminum foil, Reynolds (NASDAQ: REYN) is a household products company whose products focus on food storage, cooking, and waste.
Why Do We Pass on REYN?
- Falling unit sales over the past two years show it’s struggled to move its products and had to rely on price increases
- Estimated sales for the next 12 months are flat and imply a softer demand environment
- Gross margin of 25.5% is an output of its commoditized products
Reynolds’s stock price of $21.66 implies a valuation ratio of 13.7x forward P/E. If you’re considering REYN for your portfolio, see our FREE research report to learn more.
ASGN (ASGN)
Forward P/E Ratio: 7.6x
Evolving from its roots in IT staffing to become a high-end technology consulting powerhouse, ASGN (NYSE: ASGN) provides specialized IT consulting services and staffing solutions to Fortune 1000 companies and U.S. federal government agencies.
Why Should You Dump ASGN?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 5.4% annually over the last two years
- Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 1.2%
- Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
ASGN is trading at $39.05 per share, or 7.6x forward P/E. Dive into our free research report to see why there are better opportunities than ASGN.
One Value Stock to Watch:
AbbVie (ABBV)
Forward P/E Ratio: 14.7x
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Why Do We Like ABBV?
- Massive revenue base of $61.16 billion in a highly regulated sector makes the company difficult to replace, giving it meaningful negotiating power
- Robust free cash flow margin of 36.3% gives it many options for capital deployment
- Industry-leading 17% return on capital demonstrates management’s skill in finding high-return investments
At $208.61 per share, AbbVie trades at 14.7x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
